StemRIM Inc. announced that a patent has been registered in Russia for the application related to the novel treatment of cartilage disorders (traumatic cartilage deficiency syndrome, osteoarthritis, disseverance osteochondritis, etc.) utilizing the peptide drug developed from the "Regeneration-Inducing MedicineTM" development candidate Redasemtide (HMGB1 fragment peptide). Title of Invention: Therapeutic agent for traumatic cartilage deficiency syndrome, osteearthritis, disseverance Osteochondritis. Region.: Russia.

Application No. 2021114359. Registration No.

To be determined. Applicant. StemRIM, Osaka University.

This patent is intended to expand the indications for Redasemtide, which is currently under development, and believe that the granting of this patent will ensure the possibility of developing a drug for cartilage disorders (traumatic cart cartilage deficiency syndrome, osteOarthritis, disseverance boneochondritis, etc.) in Russia. To date, the company have been granted many patents for HMGB1 fragment peptides (including Redasemtide) in Japan, the U.S., Europe, and other countries around the world, including substance patents and medical use patents. The impact on the financial performance for the fiscal year ending July 31, 2024, is insignificant.